文献速递药疹与重症皮肤不良反应皮肤肿瘤

免疫检查点抑制剂相关皮肤毒性的流行病学与危险因素:美国人群层面分析

Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis.
PubMed 文献 · J Am Acad Dermatol · 2021-04-02

该回顾性队列研究基于美国全国保险理赔数据库,纳入8637例ICI治疗患者及8637例匹配对照。皮肤irAE总体累积发生率为25.1%,中位起病时间113天;ICI组瘙痒、黏膜炎、红皮病、斑丘疹、白癜风、扁平苔藓、大疱性类天疱疮、Grover病、皮疹、其他非特异性皮疹及药疹发生率显著更高。黑色素瘤、肾细胞癌及联合治疗者风险更高。

要点

  • ICI相关皮肤irAE总体累积发生率为25.1%,中位起病时间113天。
  • 黑色素瘤、肾细胞癌及联合治疗患者皮肤irAE风险更高。
  • 结果有助于皮肤科医生识别高危人群并指导管理。

核心结论

  • ICI治疗患者皮肤irAE累积发生率为25.1%,中位起病时间113天。
  • 黑色素瘤、肾细胞癌及联合治疗患者皮肤irAE风险更高。

研究设计与样本

  • 回顾性队列研究,基于美国全国保险理赔数据库。
  • 纳入8637例ICI治疗癌症患者及8637例匹配对照。

主要发现

  • 皮肤irAE总体累积发生率为25.1%,中位起病时间113天。
  • ICI组瘙痒、黏膜炎、红皮病、斑丘疹、白癜风、扁平苔藓、大疱性类天疱疮、Grover病、皮疹、其他非特异性皮疹及药疹发生率显著高于对照组。
  • 黑色素瘤、肾细胞癌及联合治疗患者皮肤irAE风险更高。

临床怎么用

  • 皮肤科医生可依据结果识别高危患者,辅助诊断皮肤irAE。
  • 可向转诊肿瘤科医生提供关于继续ICI治疗的管理建议。

局限性

  • 回顾性设计,无法获取患者病历数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A variety of dermatoses have been reported in the growing number of patients treated with immune-checkpoint inhibitors (ICIs), but the current understanding of cutaneous immune-related adverse events (irAEs) is limited. OBJECTIVE: To determine the cumulative incidence, distribution, and risk factors of cutaneous irAEs after ICI initiation. METHODS: This was a retrospective cohort study of patients in a national insurance claims database including cancer patients treated with ICIs and matched controls. RESULTS: The study included 8637 ICI patients and 8637 matched controls. The overall incidence of cutaneous irAEs was 25.1%, with a median onset time of 113 days. The ICI group had a significantly higher incidence of pruritus, mucositis, erythroderma, maculopapular eruption, vitiligo, lichen planus, bullous pemphigoid, Grover disease, rash, other nonspecific eruptions, and drug eruption or other nonspecific drug reaction. Patients with melanoma and renal cell carcinoma and those receiving combination therapy were at a higher risk of cutaneous irAEs. LIMITATIONS: Retrospective design without access to patient chart data. CONCLUSIONS: This study identifies cutaneous irAEs in a real-world clinical setting and highlights patient groups that are particularly at risk. The results can aid dermatologists at the bedside in the diagnosis of cutaneous irAEs and in formulating management recommendations to referring oncologists regarding the continuation of ICI therapy.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Wongvibulsin S, Pahalyants V, Kalinich M, et al. Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis. J Am Acad Dermatol. 2021. PMID: 33819538. doi:10.1016/j.jaad.2021.03.094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。